The discovery sample consisted of 15 cohorts of patients with ischaemic stroke who were of European ancestry from Europe, North America, and Australia, together with controls of matched ancestry. All studies used a case-control methodology. Most participating studies were cross-sectional, whereas four were in large, prospective, population-based cohorts (table 1).Table 1Description of cohorts used in analysis by study populationNumber of casesNumber of CS casesNumber of LVD casesNumber of SVD casesNumber of controlsAncestryStudy designGenotypingDiscovery cohortsARIC3859331638803EuropeanPopulation-basedAffymetrix 6.0ASGC11622404213101244EuropeanCross-sectionalIllumina 610BRAINS3612912097444EuropeanCross-sectionalIllumina 660CHS454147..732817EuropeanPopulation-basedIllumina 370deCODE239139925524026 970EuropeanCross-sectionalIllumina 317/370FHS17148....4164EuropeanPopulation-basedAffymetrix 550GEOS448903754498EuropeanCross-sectionalIllumina HumanOmni1HPS578......468EuropeanCross-sectionalIllumina 610HVH56688611731290EuropeanCross-sectionalIllumina 370ISGS/SWISS10702472292012329EuropeanCross-sectionalIllumina 550/610/660MGH-GASROS51616995381202EuropeanCross-sectionalAffymetrix 6.0Milano372257465407EuropeanCross-sectionalIllumina 610/660Rotterdam367......5396EuropeanPopulation-basedIllumina 550WTCCC2-Munich1174330346106797EuropeanCross-sectionalIllumina 660WTCCC2-UK23744604984745175EuropeanCross-sectionalIllumina 660Total (discovery)12 38923652167189462 004......Replication cohortsBarcelona439179110150404EuropeanCross-sectionalSequenomBSS225119390312EuropeanCross-sectionalSequenomCopenhagen730......1545EuropeanCross-sectionalTaqManESS276402069940EuropeanCross-sectionalTaqMan/Illumina 610Glasgow67512591150940EuropeanCross-sectionalSequenom/Illumina 610Go-Darts*737130259..8424EuropeanCross-sectionalAffymetrix 6.0/Illumina Cardio-metabochipGraz657116108207848EuropeanCross-sectionalSequenom/Illumina 610Interstroke*872143198238926EuropeanCross-sectionalIllumina Cardio-metabochipKrakow1235377152171584EuropeanCross-sectionalSequenomLeuven4581958363391EuropeanCross-sectionalSequenomLund4241402194466EuropeanCross-sectionalSequenomMunster12324785282241053EuropeanCross-sectionalSequenomPortugal539......507EuropeanCross-sectionalSequenomRACE (Pakistan)*13222251951891143PakistaniCross-sectionalIllumina 660SMART623303681956712EuropeanPopulation-basedSequenomSweden87615717775742EuropeanCross-sectionalSequenomVISP*1725......1047EuropeanCross-sectionalIllumina HumanOmni1WHI*3024231782099EuropeanPopulation-basedIllumina Omni-QuadTotal (replication)13 34723882434199329 083......CS=cardioembolic stroke. LVD=large-vessel disease. SVD=small-vessel disease. ARIC=The Atherosclerosis Risk in Communities study. ASGC=Australian Stroke Genetics Collabarative. BRAINS=Bio-Repository of DNA in stroke. CHS=Cardiovascular Health Study. FHS=Framingham Heart Study. GEOS=Genetics of Early-Onset Stroke. HPS=Heart Protection Study. HVH=The Heart and Vascular Health Study. ISGS/SWISS=The Ischemic Stroke Genetics Study/Sibling with Ischaemic Stroke Study. MGH-GASROS=The MGH Genes Affecting Stroke Risk and Outcome Study. WTCCC2-Munich=The Wellcome Trust Case-Control Consortium II Munich. WTCCC2-UK=The Wellcome Trust Case-Control Consortium II UK. BSS=Belgium Stroke
